Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2008

01-03-2008 | Case Report

Idiopathic retroperitoneal fibrosis: an unusual cause of low back pain

Authors: Petr Nemec, Sylva Rybnickova, Pavel Fabian, Zdenek Fojtik, Miroslav Soucek

Published in: Clinical Rheumatology | Issue 3/2008

Login to get access

Abstract

Retroperitoneal fibrosis (RPF) is a rare inflammatory disease which is characterized by the development of a fibrous process that surrounds the major vessels and organs located within the retroperitoneum. About two thirds of all cases of RPF are idiopathic and are thought to be immunological in origin. Diagnosis of RPF should be considered in patients with unexplained abdominal and low back pain and retroperitoneal lesions. We present a case report of a 59-year-old white male with idiopathic RPF with history of low back pain and weight loss as only symptoms and treated by tamoxifen, corticosteroids, and insertion of JJ endoureteric catheters due to the obstruction of the upper urinary tract.
Literature
1.
Ormond J (1948) Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 59:1072–1079PubMed
2.
McDougal WS, MacDonell RC Jr (1991) Treatment of idiopathic retroperitoneal fibrosis by immunosuppression. J Urol 145:112–114PubMed
3.
Hoffman WW, Trippel OH (1961) Retroperitoneal fibrosis: etiological considerations. J Urol 86:222–231PubMed
4.
Amis ES Jr (1991) Retroperitoneal fibrosis. AJR Am J Roentgenol 157:321–329PubMed
5.
Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ (1983) Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 52:2201–2204PubMedCrossRef
6.
Clark CP, Vanderpool D, Preskitt JT (1991) The response of retroperitoneal fibrosis to tamoxifen. Surgery 109:502–506PubMed
7.
8.
Ergun I, Keven K, Canbakan B, Ekmekci Y, Erbay B (2005) Tamoxifen in the treatment of idiopathic retroperitoneal fibrosis. Int Urol Nephrol 37:341–343PubMedCrossRef
9.
Degesys GE, Dunnick NR, Silverman PM, Cohan RH, Illescas FF, Castagno A (1986) Retroperitoneal fibrosis: use of CT in distinguishing among possible causes. AJR Am J Roentgenol 146:57–60PubMed
10.
Yuh WT, Barloon TJ, Sickels WJ, Kramolowsky EV, Williams RD (1989) Magnetic resonance imaging in the diagnosis and followup of idiopathic retroperitoneal fibrosis. J Urol 141:602–605PubMed
11.
Kubota Y, Nomura Y, Tamaki M, Maeda S, Deguchi T (2005) Four cases of idiopathic retroperitoneal fibrosis markedly responsive to steroid therapy. Hinyokika Kiyo 51:315–319PubMed
12.
Kardar AH, Kattan S, Lindstedt E, Hanash K (2002) Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 168:550–555PubMedCrossRef
13.
Hollingworth P, Denman AM, Gumpel JM (1980) Retroperitoneal fibrosis and polyarteritis nodosa successfully treated by intensive immunosuppression. J R Soc Med 73:61–64PubMed
14.
Maillart E, Laueriere L, Kassis S, Moulonguet-Doleris L, Prinseau J, Baglin A et al (2006) Is there an evidence-based management of idiopathic retroperitoneal fibrosis? Rev Med Interne 27:854–857PubMedCrossRef
15.
Horgan K, Cooke E, Hallett MB, Mansel RE (1986) Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 35:4463–4465PubMedCrossRef
Metadata
Title
Idiopathic retroperitoneal fibrosis: an unusual cause of low back pain
Authors
Petr Nemec
Sylva Rybnickova
Pavel Fabian
Zdenek Fojtik
Miroslav Soucek
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0736-5

Other articles of this Issue 3/2008

Clinical Rheumatology 3/2008 Go to the issue

Brief Report

Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine

Brief Report

Buerger’s disease: a 10-year experience in Tehran, Iran

Case Report

Pedicle stress fracture: an unusual complication of pycnodysostosis

Original Article

Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies

Letter to the Editor

Is anticoagulation unnecessary in Behcet’s disease with deep venous thrombosis?

Original Article

Quality of life assessments with SF 36 in different musculoskeletal diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits